SEARCH

SEARCH BY CITATION

The current issue of Cancer includes a report on a concise, randomized controlled trial (RCT) with long-term follow-up that favors combined androgen blockade with bicalutamide versus lutenizing hormone-releasing hormone monotherapy in Japanese men with locally advanced and metastatic prostate cancer. It has been 20 years since the first RCT on CAB was published, and the debate continues.